|
Parameters
|
E-cadherin
|
P
|
β-cadherin
|
P
|
S100A4
|
P
|
|---|
| |
Strong (n = 208)
|
Weak or Loss (n = 97)
| |
Nuclear, Low (n = 267)
|
Nuclear, High (n = 38)
| |
Low (n = 267)
|
High (n = 267)
| |
|---|
|
Preoperative CEA (ng/ml)
|
7.0 ± 22.5
|
6.5 ± 12.4
|
0.811
|
6.5 ± 19.8
|
8.4 ± 18.3
|
0.573
|
5.3 ± 13.1
|
12.5 ± 35.7
|
0.014
|
|
MSI status (n = 166)
| | |
0.167
| |
0.004
| | |
0.386
|
|
MSI-H (n = 8)
|
3(37.2)
|
5(62.5)
| |
8(100.0)
|
0(0.0)
| |
7(87.5)
|
1(12.5)
| |
|
MSI-L (n = 6)
|
3(50.0)
|
3(50.0)
| |
4(66.7)
|
2(33.3)
| |
5(83.3)
|
1(16.7)
| |
|
MSS (n = 135)
|
91(67.4)
|
44(32.6)
| |
107(81.1)
|
25(18.9)
| |
107(80.5)
|
26(19.5)
| |
|
Tumor Location
| | |
0.455
| |
0.037
| | |
0.704
|
|
Right (n = 66)
|
48(72.7)
|
18(27.3)
| |
*6.5 ± 18.7
| |
60(87.0)
|
9(13.0)
| |
|
Left (n = 236)
|
158(66.9)
|
78(33.1)
| |
*12.2 ± 22.7
| |
194(84.0)
|
37(16.0)
| |
|
Tumor Budding
| |
0.011
| |
0.799
| |
0.480
|
|
Low (<10) (n = 263)
|
188(70.9)
|
77(29.1)
| |
230(87.1)
|
34(12.9)
| |
224(85.2)
|
39(14.8)
| |
|
High (≥ 10) (n = 40)
|
20(50.0)
|
20(50.0)
| |
37(90.2)
|
4(9.8)
| |
32(80.0)
|
8(20.0)
| |
|
Macroscopic Tumor Type
| | |
0.616
| |
0.909
| | |
0.038
|
|
Polypoid (n = 21)
|
17(77.3)
|
5(22.7)
| |
18(85.7)
|
3(14.3)
| |
21(100.0)
|
0(0.0)
| |
|
Ulcerofungating (n = 160)
|
109(66.9)
|
54(33.1)
| |
143(88.3)
|
19(11.7)
| |
138(86.3)
|
22(13.8)
| |
|
Ulceroinfiltrative (n = 122)
|
82(68.3)
|
38(31.7
| |
106(86.9)
|
16(13.1)
| |
97(79.5)
|
25(20.5)
| |
|
Tumor Grade
| |
0.735
| |
0.817
| |
0.577
|
|
Well (n = 73)
|
53(72.6)
|
20(27.4)
| |
64(86.5)
|
10(13.5)
| |
60(82.2)
|
13(17.8)
| |
|
Moderate or Poor (n = 227)
|
151(66.5)
|
73(34.0)
| |
196(87.5)
|
28(12.5)
| |
191(85.3)
|
33(14.7)
| |
|
Ratio of Metastatic Lymph Node
|
0.11 ± 0.19
|
0.13 ± 0.21
|
0.567
|
0.12 ± 0.20
|
0.09 ± 0.19
|
0.317
|
0.11 ± 0.19
|
0.18 ± 0.23
|
0.019
|
|
Nodal Stages
| |
0.567
| |
0.288
| |
0.002
|
|
N0 (n = 178)
|
128(70.3)
|
54(29.7)
| |
155(85.2)
|
27(14.8)
| |
161(90.4)
|
17(9.6)
| |
|
N1 (n = 77)
|
49(63.6)
|
28(36.4)
| |
69(92.0)
|
6(8.0)
| |
57(74.0)
|
20(26.0)
| |
|
N2 (n = 48)
|
31(67.4)
|
15(32.6)
| |
43(89.6)
|
5(10.4)
| |
38(79.2)
|
10(20.8)
| |
|
Depth of Invasion
| |
0.513
| |
1.000
| |
0.010
|
|
T1, T2 (n = 50)
|
38(73.1)
|
14(26.9)
| |
44(88.0)
|
6(12.0)
| |
48(96.0)
|
2(4.0)
| |
|
T3, T4 (n = 253)
|
170(67.2)
|
83(32.8)
| |
223(87.5)
|
32(12.5)
| |
208(82.2)
|
45(17.8)
| |
|
AJCC stage
| |
0.272
| |
0.669
| |
0.001
|
|
I (n = 39)
|
27(67.5)
|
13(32.5)
| |
35(87.5)
|
5(12.5)
| |
37(94.9)
|
2(5.1)
| |
|
II (n = 133)
|
96(71.1)
|
39(28.9)
| |
114(85.1)
|
20(14.9)
| |
119(89.5)
|
14(10.5)
| |
|
III (n = 110)
|
74(68.5)
|
34(31.5)
| |
97(89.8)
|
11(10.2)
| |
81(73.6)
|
29(26.4)
| |
|
IV (n = 21)
|
11(50.0)
|
11(50.0)
| |
21(91.3)
|
2(8.7)
| |
19(90.5)
|
2(9.5)
| |
|
Lymphovascular Invasion
| |
0.891
| |
0.341
| |
0.050
|
|
Negative
|
150(68.5)
|
69(31.5)
| |
195(88.6)
|
25(11.4)
| |
189(87.1)
|
28(12.9)
| |
|
Positive
|
57(67.1)
|
28(32.9)
| |
72(84.7)
|
13(15.3)
| |
66(77.6)
|
19(22.4)
| |
|
Neural Invasion
| |
0.037
| |
0.507
| |
0.050
|
|
Negative
|
196(69.8)
|
85(30.2)
| |
248(87.9)
|
34(12.1)
| |
240(85.7)
|
40(14.3)
| |
|
Positive
|
11(47.8)
|
12(52.2)
| |
19(82.6)
|
4(17.4)
| |
15(68.2)
|
7(31.8)
| |
|
Lymphocyte infiltration
| |
0.325
| | |
0.821
| |
< 0.0001
|
|
Mild
|
70(72.9)
|
26(27.1)
| |
88(88.9)
|
11(11.1)
| |
70(71.4)
|
28(28.6)
| |
|
Moderate
|
108(67.1)
|
53(32.9)
| |
138(86.3)
|
22(13.8)
| |
144(89.4)
|
17(10.6)
| |
|
Severe
|
26(60.5)
|
17(39.5)
| |
36(87.8)
|
5(12.2)
| |
38(95.0)
|
2(5.0)
| |
|
Type of Tumor Growth
| |
0.159
| |
1.000
| |
0.044
|
|
Expanding
|
79(73.1)
|
29(26.9)
| |
93(87.7)
|
13(12.3)
| |
96(90.6)
|
10(9.4)
| |
|
Infiltrative
|
125(65.1)
|
67(34.9)
| |
168(87.0)
|
25(13.0)
| |
156(81.3)
|
36(18.8)
| |
- Lymph Node Ratio, number of metastatic lymph nodes / number of harvested lymph nodes; CEA carcinoembryonic antigen serum level, *, percentage of β-catenin nuclear expression at invasive margin.
